Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a 2.02% increase in value on September 30, with a trading volume of 136 million yuan, despite a reduction in shares outstanding [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 555 million yuan [1] - Since its inception on August 20, 2025, the fund has returned 1.17% [1] - Over the past month, the fund has achieved a return of 3.44% [1] Group 2: Share Dynamics - On the reporting date, the fund's shares decreased by 9 million, bringing the total outstanding shares to 549 million [1] - In the last 20 trading days, the fund's shares have decreased by 11 million [1] Group 3: Benchmark and Management - The fund's performance benchmark is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1]
9月30日港股创新药ETF鹏华（159286）份额减少900.00万份
Xin Lang Cai Jing·2025-10-09 01:12